Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Edinburgh Drug Discovery |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
Janssen Pharmaceuticals and Johns Hopkins To Develop New Therapies to Treat Neurological DiseasesJanssen Pharmaceuticals (Formerly OMJPI) a Johnson and Johnson entity has entered into collaboration agreement with Johns Hopkins Brain Science Institute ("BSi") at Johns Hopkins University. Janssen will be working with Johns Hopkins researchers... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all CWHM/OWH Childhood DiarrheaCWHM signed a joint research agreement in 2010 with the Institute for One World Health to discover and develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5. Under the agreement, CWHM... View all |
No EVENTS for listing |
No Job Posts |
